Strontium-89 for palliation of bone pain [2]

Medical and Pediatric Oncology

Volumn 40, Issue 2, 2003, Pages 136-

  Gompakis, Nikos ^a   Triantafyllou, P ^a   Sidi, B ^b   Koliouskas, E D ^b   Salem, N ^c   Pistevou, K ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b Aristotle University and Hippokration General Hospital   (Greece)

^c Institute of Thessaloniki   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; MORPHINE; STRONTIUM 89;

ANALGESIA; ANTINEOPLASTIC ACTIVITY; BONE DEVELOPMENT; BONE METASTASIS; BONE PAIN; CANCER INHIBITION; CANCER PALLIATIVE THERAPY; CASE REPORT; CYTOTOXICITY; FEMALE; HUMAN; INFUSION; LETTER; OSTEOSARCOMA; PRESCHOOL CHILD; PRIORITY JOURNAL; QUALITY OF LIFE; RADIATION ABSORPTION; RADIATION DOSE;

BONE NEOPLASMS; CHILD, PRESCHOOL; FEMALE; HUMANS; OSTEOSARCOMA; PAIN; PALLIATIVE CARE; STRONTIUM RADIOISOTOPES;

EID: 0037291545     PISSN: 00981532     EISSN: None     Source Type: Journal    
DOI: 10.1002/mpo.10118     Document Type: Letter

References (7)

1. Charron M, Brown M, Rowland P, et al. Pain palliation with strontium-89 in children with metastatic disease. Med Pediatr Oncol 1996;26:393-396.
2. Silberstein EB, Eugene L, Saenger SR. Painful osteoblastic metastases: The role of nuclear medicine. Oncology 2001;15:157-163; Discussion 167-170, 174.
3. Laing AH. et al. Strontium-89 chloride for pain palliation in prostatic skeletal malignancy. Br J Radiol 1991;64:816-822.
4. Robinson RG, Preston DF, Schiefelbein M. et al. Strontium 89 therapy for the palliation of pain due to osseous metastases. JAMA 1995;274:420-424.
5. Baumrucker S. Palliation of painful bone metastases: Strontium-89. Am J Hosp Palliat Care 1998;15:113-115.
6. Fuster D, Herranz D. Vidal-Sicart S. et al. Usefulness of strontium-89 for bone pain palliation in metastatic breast cancer patients. Nucl Med Comm 2000;21:623-626.
7. Robinson RG, Preston DF, Baxter KG, et al. Clinical experience with strontium-89 in prostatic and breast cancer patients. Semin Oncol 1993;20(3 Suppl 2):44-48.